Tuberculosis Screening in the Ambulatory Setting
Clinical Pathways promote evidence-based, safe, and high-value patient care by providing clinical recommendations and standard processes. They are developed by multidisciplinary committees of subject matter experts, informed by a methodical review of available evidence and consensus among committee members.
Clinical Pathway:
- Tuberculosis Screening in the Ambulatory Setting algorithm
- Tuberculosis Screening in the Ambulatory Setting synopsis
Inclusion and exclusion criteria:
- Inclusion:
- Patients presenting to the ambulatory setting with caregiver or clinician concerns for TB infection or disease
- Exclusion:
- Patients without concern for TB infection or disease (e.g., patients who received a general community exposure notification)
- Patients previously diagnosed with TB infection or disease who have been adequately treated and have no signs or symptoms of active disease
Committee members involved in the development:
- Kathy Auten, MSN, RN, CIC | Infection Prevention & Control | Committee Chair
- Christelle Ilboudo, MD | Infectious Diseases, Infection Prevention & Control | Committee Chair
- Theodore Barnett, MD | Emergency Department | Committee Member
- Danny Dooling, MD | Med/Peds Resident | Committee Member
- Anik Patel, MD, FAAP | Emergency Department, Global Health | Committee Member
- Gretchen Range, RN, BSN, CPN | Urgent Care | Committee Member
- Douglas Swanson, MD | Infectious Diseases | Committee Member
EBP Committee Members:
- Todd Glenski, MD, MSHA, FASA
- Megan Gripka, MT (ASCP) SM
Publication dates:
- Finalized date: 04/2025
- Next expected revision date: 2028
Concerns with content:
If you have any questions regarding this content or identify a broken link, please email evidencebasedpractice@cmh.edu.